Voting Rights and Shares Capital of the Company

Nanobiotix (NASDAQ: NBTX) disclosed its voting rights and share count as of January 31, 2026.

Rhea-AI Summary

Nanobiotix (NASDAQ: NBTX) disclosed its voting rights and share count as of January 31, 2026. The company reported 48,450,358 shares outstanding, 50,153,460 theoretical voting rights and 50,131,342 exercisable voting rights.

The release explains methodology for theoretical vs exercisable voting rights and lists contact details for investor and media relations.

Argus Feb 18 session

+1.15% close to close Open Argus

Details

News Market Reaction – NBTX

On Feb 18, the first trading day after this news, NBTX closed 1.15% above the previous close.

Data tracked by StockTitan Argus for the Feb 18 session.

Market Context

This announcement details NANOBIOTIX’s share count and both theoretical and exercisable voting right...

Analysis

This announcement details NANOBIOTIX’s share count and both theoretical and exercisable voting rights as of January 31, 2026, in line with French disclosure requirements. It confirms 48,450,358 shares outstanding and helps investors track capital structure evolution alongside earlier monthly notices. In evaluating this update, investors may contextualize it with prior financial and clinical communications and monitor future operational milestones and financing developments disclosed via similar regulatory channels.

Key Figures

Shares outstanding: 48,450,358 Total voting rights (theoretical): 50,153,460 Exercisable voting rights: 50,131,342 +5 more

Shares outstanding

48,450,358

As of January 31, 2026

Total voting rights (theoretical)

50,153,460

As of January 31, 2026

Exercisable voting rights

50,131,342

As of January 31, 2026

Patent families

More than 25

Associated with three nanotechnology platforms

Nanotechnology platforms

3

Oncology, bioavailability/biodistribution, CNS disorders

Year incorporated

2003

Nanobiotix corporate history

52-week high

$30.35

Pre-news 52-week price range

52-week low

$2.95

Pre-news 52-week price range

Historical Context

5 past events · Latest: Jan 13

5 events

1. Jan 13

   Voting-rights update

   24h Move

   +0.7%

   Reported Dec 31, 2025 share count and theoretical/exercisable voting rights.

2. Dec 17

   Voting-rights update

   24h Move

   +3.1%

   Disclosed Nov 30, 2025 voting-rights and share-capital figures under French rules.

3. Dec 15

   Index inclusion

   24h Move

   -1.6%

   Announced inclusion in CAC Mid 60 and SBF 120 indices on Euronext Paris.

4. Nov 24

   Ops/financial update

   24h Move

   +5.1%

   Detailed Q3 2025 update, royalty financing and extended cash visibility to early 2028.

5. Nov 14

   Voting-rights update

   24h Move

   +2.6%

   Released Oct 31, 2025 share count and theoretical vs exercisable voting rights.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

isin, voting rights, nanotechnology

3 terms

isin financial

"Market: Euronext Paris / NasdaqEuronext Compartment: B ISIN code: FR0011341205"

A 12-character International Securities Identification Number (ISIN) is a unique code that acts like a passport for a specific stock, bond or other tradable security so it can be identified worldwide. Investors and systems use it to ensure they are buying, selling and tracking the exact same instrument across exchanges and data feeds, which prevents costly mix-ups and makes portfolio reporting, settlement and regulatory checks simpler and more reliable.

View in glossary

voting rights regulatory

"Date | Number of Shares Outstanding | Total number of voting rights"

Voting rights are the ability of shareholders to have a say in important company decisions, like choosing leaders or approving big changes. They matter because they give owners a voice in how the company is run, similar to how voters influence elections, ensuring the company acts in shareholders’ interests.

nanotechnology medical

"more than 25 patent families associated with three (3) nanotechnology platforms"

Nanotechnology is the design and control of materials and devices at the scale of atoms and molecules — about one-billionth of a meter — allowing scientists to create properties and functions not possible at larger sizes. For investors, it matters because these tiny changes can lead to big improvements in drugs, electronics, materials and manufacturing efficiency, opening new markets and competitive advantages while also bringing technical, cost and regulatory risks.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

In accordance with articles L.233-8 II of the French Commercial Code and 223-16 of the General Regulation of the French Financial Markets Authority (Autorité des Marchés Financiers)

PARIS, Feb. 17, 2026 (GLOBE NEWSWIRE) --
Market: Euronext Paris / Nasdaq
Euronext Compartment: B
ISIN code: FR0011341205
Nasdaq: NBTX
Bloomberg: NANO:FP
Reuters: NANO.PA
Website: www.nanobiotix.com

Date	Number of Shares Outstanding	Total number of voting rights
		Total voting rights, theoretical1	Total voting rights, exercisable2
January 31, 2026	48,450,358	50,153,460	50,131,342

About NANOBIOTIX

Nanobiotix is a late-stage clinical biotechnology company pioneering disruptive, physics-based therapeutic approaches to revolutionize treatment outcomes for millions of patients; supported by people committed to making a difference for humanity. The Company’s philosophy is rooted in the concept of pushing past the boundaries of what is known to expand possibilities for human life.

Incorporated in 2003, Nanobiotix is headquartered in Paris, France and is listed on Euronext Paris since 2012 and on the Nasdaq Global Select Market in New York City since December 2020. The Company has subsidiaries in Cambridge, Massachusetts (United States) amongst other locations.

Nanobiotix is the owner of more than 25 patent families associated with three (3) nanotechnology platforms with applications in 1) oncology; 2) bioavailability and biodistribution; and 3) disorders of the central nervous system.

For more information about Nanobiotix, visit us at www.nanobiotix.com or follow us on LinkedIn and Twitter.

________________________________

¹ The total number of theoretical (or “gross”) voting rights is used as the basis for calculating threshold crossings. In accordance with Article 223-11 of the AMF General Regulations, this number is calculated on the basis of all shares to which voting rights are attached, including those for which voting rights have been suspended.

² The total number of exercisable at a shareholders’ meeting (or “net”) voting rights is calculated without taking into account shares for which voting rights have been suspended as shares held in treasury by the Company. It is released in order to ensure that the public is properly informed.

Contacts

Nanobiotix
Communications Department Brandon Owens VP, Communications +1 (617) 852-4835 contact@nanobiotix.com	Investor Relations Department Joanne Choi VP, Investor Relations (US) +1 (713) 609-3150 Ricky Bhajun Director, Investor Relations (EU) investors@nanobiotix.com
Media Relations
France – HARDY Caroline Hardy +33 06 70 33 49 50 carolinehardy@outlook.fr	Global – uncapped Becky Lauer +1 (646) 286-0057 uncappednanobiotix@uncappedcommunications.com

Attachments

• 2026-02-17 -- NBTX -- Voting Rights & Shares Capital -- FINAL

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many shares outstanding did Nanobiotix report on January 31, 2026 (NBTX)?

Nanobiotix reported 48,450,358 shares outstanding as of January 31, 2026. According to Nanobiotix, this figure is the basis for calculating theoretical voting rights under applicable AMF rules and is published to inform shareholders.

What were Nanobiotix's total theoretical and exercisable voting rights on January 31, 2026 (NBTX)?

The company reported 50,153,460 theoretical and 50,131,342 exercisable voting rights on January 31, 2026. According to Nanobiotix, theoretical rights include suspended rights, while exercisable rights exclude treasury-held shares.

Why does Nanobiotix publish both theoretical and exercisable voting rights (NBTX)?

Publishing both numbers ensures transparency about voting thresholds and shareholder rights. According to Nanobiotix, theoretical rights include all attached voting rights; exercisable rights exclude shares with suspended voting rights like treasury shares.

Where can investors find Nanobiotix contact details for voting rights questions (NBTX)?

Investor and media contact details are provided in the disclosure for follow-up. According to Nanobiotix, dedicated investor relations and communications contacts are listed to assist shareholders with queries about the voting rights data.

Which regulatory articles govern Nanobiotix's voting rights disclosure (NBTX)?

The disclosure cites Article L.233-8 II of the French Commercial Code and Article 223-16 of the AMF General Regulation. According to Nanobiotix, these provisions require publishing share counts and voting-rights data to inform the market.